Our technology

Bold Therapeutics' lead development candidate is BOLD-100, a novel first-in-class anti-resistance therapy for the treatment of gastric, pancreatic and other cancers in combination with existing anti-cancer therapies. BOLD-100 has demonstrated synergy in established preclinical models in combination with a wide variety of anti-cancer therapies including traditional chemotherapies, tyrosine kinase inhibitors and checkpoint inhibitors.
BOLD-100 successfully completed a Phase 1 monotherapy study and was subsequently granted an Orphan Drug Designation (ODD) in pancreatic cancer. Additional ODDs are expected in the next 18 months. Bold Therapeutics expects to initiate a combination Phase 1/2 study in late 2019 at various sites in Canada and the United States.